当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

Abstract：

:Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m(2) was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity profile was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Mayer J,Krejcí M,Doubek M,Pospísil Z,Brychtová Y,Tomíska M,Rácil Z

doi

10.1038/sj.bmt.1704829

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

699-705

issue

7

eissn

0268-3369

issn

1476-5365

pii

1704829

journal_volume

35

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

    abstract：:The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/bmt.2010.249

    authors： Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

    更新日期：2011-08-01 00:00:00

  • Sexual function 1-year after allogeneic hematopoietic stem cell transplantation.

    abstract：:Treatment with allogeneic hematopoietic stem cell transplantation (HSCT) is associated with short and long-term toxicities that can result in alterations in sexual functioning. The aims of this prospective evaluation were to determine: (1) associations between HSCT and increased sexual dysfunction 1 year after treatme...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.342

    authors： Noerskov KH,Schjødt I,Syrjala KL,Jarden M

    更新日期：2016-06-01 00:00:00

  • Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.

    abstract：:Certain leukemias have a high relapse risk even after allo-SCT, and GVHD prophylaxis with calcineurin inhibitors (CNIs) may interfere with a possible GVL effect. Therefore, we replaced CYA by sirolimus in patients with high relapse risk. In contrast to CNIs, sirolimus promotes the generation of regulatory T-cells and ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2008.377

    authors： Schleuning M,Judith D,Jedlickova Z,Stübig T,Heshmat M,Baurmann H,Schwerdtfeger R

    更新日期：2009-05-01 00:00:00

  • Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

    abstract：:We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 x 107 CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m(2)/4 days and melphalan 70 mg/m(2)/2 days. GVHD prophylaxis consisted of cyclospo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702726

    authors： de Lima M,Bonamino M,Vasconcelos Z,Colares M,Diamond H,Zalcberg I,Tavares R,Lerner D,Byington R,Bouzas L,da Matta J,Andrade C,Carvalho L,Pires V,Barone B,Maciel C,Tabak D

    更新日期：2001-01-01 00:00:00

  • Combination antifungal therapy: what can and should we expect?

    abstract：:Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well est...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1705687

    authors： Johnson MD,Perfect JR

    更新日期：2007-08-01 00:00:00

  • Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

    abstract：:This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of tran...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Demirer T,Gooley T,Buckner CD,Petersen FB,Lilleby K,Rowley S,Sanders J,Storb R,Appelbaum FR,Bensinger WI

    更新日期：1995-06-01 00:00:00

  • Prompt and durable hematopoietic reconstitution by unrelated cord blood transplantation in a child with Fanconi anemia.

    abstract：:We describe here the case of an 8-year-old girl with Fanconi anemia (FA) whose hematopoiesis was successfully restored by unrelated umbilical cord blood (UCB) transplantation. The patient became resistant to androgen therapy, and developed intracranial hemorrhage and dyserythropoiesis. Her hematopoietic recovery after...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702876

    authors： Yoshimasu T,Tanaka R,Suenobu S,Yagasaki H,Yoshino H,Ueda T,Hisakawa H,Ishii T,Mitsui T,Ebihara Y,Manabe A,Iseki T,Maekawa T,Nakahata T,Asano S,Tsuji K

    更新日期：2001-04-01 00:00:00

  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.

    abstract：:Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703039

    authors： Bhagat R,Sporn TA,Long GD,Folz RJ

    更新日期：2001-05-01 00:00:00

  • The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.

    abstract：:In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 m...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1705846

    authors： Nasilowska-Adamska B,Rzepecki P,Manko J,Czyz A,Markiewicz M,Federowicz I,Tomaszewska A,Piatkowska-Jakubas B,Wrzesien-Kus A,Bieniaszewska M,Duda D,Szydlo R,Halaburda K,Szczepinski A,Lange A,Hellman A,Robak T,Skotnicki A

    更新日期：2007-11-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-0857-x

    authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期：2020-10-01 00:00:00

  • Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

    abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,meta分析

    doi：10.1038/bmt.2016.222

    authors： Landgren O,Devlin S,Boulad M,Mailankody S

    更新日期：2016-12-01 00:00:00

  • T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.

    abstract：:Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2014.62

    authors： Bashey A,Solomon SR

    更新日期：2014-08-01 00:00:00

  • Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization.

    abstract：:Sequential administration of high-dose chemotherapy courses possibly allows extensive in vivo purging before circulating progenitor collection for autograft. To evaluate whether progenitor cell mobilization was negatively affected by repeated high-dose chemotherapy courses, we studied 23 lymphoma patients undergoing t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Tarella C,Caracciolo D,Gavarotti P,Bondesan P,Cherasco C,Omedè P,Bregni M,Siena S,Gianni AM,Pileri A

    更新日期：1995-08-01 00:00:00

  • Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model.

    abstract：:New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2008.279

    authors： Kanold J,Paillard C,Tchirkov A,Merlin E,Marabelle A,Lutz P,Rousseau R,Baldomero H,Deméocq F

    更新日期：2008-10-01 00:00:00

  • Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

    abstract：:Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fl...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0660-8

    authors： Shadman M,Maloney DG,Storer B,Sandmaier BM,Chauncey TR,Smedegaard Andersen N,Niederwieser D,Shizuru J,Bruno B,Pulsipher MA,Maziarz RT,Agura ED,Hari P,Langston AA,Maris MB,McSweeney PA,Storb R,Sorror ML

    更新日期：2020-01-01 00:00:00

  • Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

    abstract：:We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days). The tim...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701646

    authors： Perry JJ,Fleming RA,Rocco MV,Petros WP,Bleyer AJ,Radford JE Jr,Powell BL,Hurd DD

    更新日期：1999-04-01 00:00:00

  • Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.

    abstract：:One hundred and one donors who had received filgrastim (rhG-CSF) for the purpose of donating either granulocytes or peripheral blood stem cells (PBSC) for their relatives more than 3 years ago were contacted. All donors had received daily rhG-CSF at a median dose of 16 microg/kg/day (range 3-16) for a median of 6 days...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702072

    authors： Cavallaro AM,Lilleby K,Majolino I,Storb R,Appelbaum FR,Rowley SD,Bensinger WI

    更新日期：2000-01-01 00:00:00

  • Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.

    abstract：:The aim of this study was to develop a comprehensive system for predicting non-relapse mortality after allogeneic hematopoietic cell transplantation (HCT) during first complete remission (CR) of acute myeloid leukemia (AML). After dividing 2344 eligible patients randomly into a training set and a validation set, we fi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01032-9

    authors： Yanada M,Konuma T,Mizuno S,Saburi M,Shinohara A,Tanaka M,Marumo A,Sawa M,Uchida N,Ozawa Y,Onizuka M,Yoshioka S,Nakamae H,Kondo T,Kimura T,Kanda J,Fukuda T,Atsuta Y,Nakasone H,Yano S

    更新日期：2020-08-14 00:00:00

  • Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?

    abstract：:Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2009.214

    authors： Freytes CO,Lazarus HM

    更新日期：2009-11-01 00:00:00

  • Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.

    abstract：:Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapse-fr...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1701941

    authors： Kanteti R,Miller K,McCann J,Roitman D,Morelli J,Hurley C,Berkman E,Schenkein D

    更新日期：1999-09-01 00:00:00

  • Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.

    abstract：:Cytomegalovirus (CMV) represents a major cause of morbidity after allogeneic stem cell transplantation (allo-SCT). Using interferon-gamma-enzyme-linked immunospot (ELISPOT) assay and HLA-peptide tetramers, we analysed 54 patients who received a reduced-intensity conditioning regimen, including fludarabine, busulphan a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704442

    authors： Mohty M,Mohty AM,Blaise D,Faucher C,Bilger K,Isnardon D,Sainty D,Gastaut JA,Viens P,Olive D,Gaugler B

    更新日期：2004-04-01 00:00:00

  • Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.

    abstract：:Children with multisystem Langerhans cell histiocytosis (LCH) and risk organ involvement who fail to respond to conventional chemotherapy have an extremely poor prognosis. Myeloablative stem cell transplantation (SCT) as a possible salvage approach for these patients has been associated with a high risk of transplant-...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705015

    authors： Steiner M,Matthes-Martin S,Attarbaschi A,Minkov M,Grois N,Unger E,Holter W,Vormoor J,Wawer A,Ouachee M,Woessmann W,Gadner H

    更新日期：2005-08-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract：:Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/bmt.2015.205

    authors： Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期：2016-01-01 00:00:00

  • Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc

    abstract：:These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other immune-mediated neurological diseases and provide recommendations for patient selection, transplant technique, follow-up and fut...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0684-0

    authors： Sharrack B,Saccardi R,Alexander T,Badoglio M,Burman J,Farge D,Greco R,Jessop H,Kazmi M,Kirgizov K,Labopin M,Mancardi G,Martin R,Moore J,Muraro PA,Rovira M,Sormani MP,Snowden JA,European Society for Blood and Marrow Tr

    更新日期：2020-02-01 00:00:00

  • Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.

    abstract：:Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We analyzed the clinical outcome of ABO incompatibility after allogeneic PBSCT. A total of 89 consecutive adult patients with hematological dise...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704816

    authors： Kim JG,Sohn SK,Kim DH,Baek JH,Lee KB,Min WS,Kim CC,Lee MH,Lee JJ,Chung IJ,Kim HJ,Lee JW

    更新日期：2005-03-01 00:00:00

  • Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours.

    abstract：:Reverse transcriptase polymerase chain reaction (RT-PCR) was applied to evaluate the frequency of tumour cells in PBPC products from 15 high risk Ewing tumour (ET) patients who were treated according to EICESS 92 with high-dose chemotherapy (HDC) and stem cell rescue. Initial tumour cell contamination of the bone marr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701924

    authors： Fischmeister G,Zoubek A,Jugovic D,Witt V,Ladenstein R,Fritsch G,Höcker P,Gadner H,Kovar H

    更新日期：1999-08-01 00:00:00

  • Biological characterization of CD34+ cells mobilized into peripheral blood.

    abstract：:We review here the functional and kinetic characteristics of highly purified hematopoietic CD34+ mobilized into peripheral blood (PB) by granulocyte colony-stimulating factor (G-CSF) with or without chemotherapy for autologous or allogeneic transplantation. Circulating CD34+ cells were evaluated for their colony-formi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Lemoli RM,Tafuri A,Fortuna A,Catani L,Rondelli D,Ratta M,Tura S

    更新日期：1998-12-01 00:00:00

  • Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation.

    abstract：:The development of immune-mediated hemolytic anemia is a well-recognized complication after allogeneic bone marrow transplantation (BMT). The majority of reported cases, however, have been alloimmune in origin due to ABO or minor red blood cell antigen incompatibilities between the donor and recipient. In this study, ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Drobyski WR,Potluri J,Sauer D,Gottschall JL

    更新日期：1996-06-01 00:00:00

  • The pattern of change in salivary immunoglobulins and antibodies to S. mitis and S. oralis in children undergoing bone marrow transplantation: use of an indirect method of assessment.

    abstract：:The objective of this study was to assess the pattern of change in salivary immunoglobulins and antibodies to S. mitis and S. oralis in 23 children following allogeneic bone marrow transplantation and their matched controls. To overcome the difficulty of obtaining a sufficient quantity of whole saliva from very young,...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701968

    authors： Lucas V,Marchant S,Challacombe S,Roberts G,Beighton D

    更新日期：1999-09-01 00:00:00

  • Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.

    abstract：:Thrombotic microangiopathy (TM), manifesting clinically as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, is an uncommon complication after bone marrow transplantation (BMT). A retrospective analysis of potential risk factors for TM following allogeneic BMT was performed. Clinical data were analyzed...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701359

    authors： Paquette RL,Tran L,Landaw EM

    更新日期：1998-08-01 00:00:00